Browse ST6GAL1

Summary
SymbolST6GAL1
NameST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Aliases ST6Gal I; SIAT1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase); ST6GalI; ST6N; B-cell an ......
Chromosomal Location3q27.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus, Golgi stack membrane; Single-pass type II membrane protein. Secreted. Note=Membrane-bound form in trans cisternae of Golgi. Secreted into the body fluid.
Domain PF00777 Glycosyltransferase family 29 (sialyltransferase)
Function

Transfers sialic acid from CMP-sialic acid to galactose-containing acceptor substrates.

> Gene Ontology
 
Biological Process GO:0006054 N-acetylneuraminate metabolic process
GO:0006486 protein glycosylation
GO:0006487 protein N-linked glycosylation
GO:0006493 protein O-linked glycosylation
GO:0006959 humoral immune response
GO:0009100 glycoprotein metabolic process
GO:0009101 glycoprotein biosynthetic process
GO:0009311 oligosaccharide metabolic process
GO:0016266 O-glycan processing
GO:0018196 peptidyl-asparagine modification
GO:0018279 protein N-linked glycosylation via asparagine
GO:0043413 macromolecule glycosylation
GO:0044723 single-organism carbohydrate metabolic process
GO:0070085 glycosylation
GO:0097503 sialylation
Molecular Function GO:0003835 beta-galactoside alpha-2,6-sialyltransferase activity
GO:0008373 sialyltransferase activity
GO:0016757 transferase activity, transferring glycosyl groups
Cellular Component GO:0005795 Golgi stack
GO:0030173 integral component of Golgi membrane
GO:0031228 intrinsic component of Golgi membrane
GO:0031300 intrinsic component of organelle membrane
GO:0031301 integral component of organelle membrane
GO:0031984 organelle subcompartment
GO:0031985 Golgi cisterna
GO:0032580 Golgi cisterna membrane
GO:0098791 Golgi subcompartment
> KEGG and Reactome Pathway
 
KEGG hsa00510 N-Glycan biosynthesis
hsa00514 Other types of O-glycan biosynthesis
hsa01100 Metabolic pathways
Reactome R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-446193: Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein
R-HSA-392499: Metabolism of proteins
R-HSA-975577: N-Glycan antennae elongation
R-HSA-975576: N-glycan antennae elongation in the medial/trans-Golgi
R-HSA-5173105: O-linked glycosylation
R-HSA-913709: O-linked glycosylation of mucins
R-HSA-597592: Post-translational protein modification
R-HSA-4085001: Sialic acid metabolism
R-HSA-446219: Synthesis of substrates in N-glycan biosythesis
R-HSA-977068: Termination of O-glycan biosynthesis
R-HSA-948021: Transport to the Golgi and subsequent modification
Summary
SymbolST6GAL1
NameST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Aliases ST6Gal I; SIAT1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase); ST6GalI; ST6N; B-cell an ......
Chromosomal Location3q27.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ST6GAL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolST6GAL1
NameST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Aliases ST6Gal I; SIAT1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase); ST6GalI; ST6N; B-cell an ......
Chromosomal Location3q27.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ST6GAL1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolST6GAL1
NameST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Aliases ST6Gal I; SIAT1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase); ST6GalI; ST6N; B-cell an ......
Chromosomal Location3q27.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ST6GAL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14121.230.0149
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)651.1750.615
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.2730.453
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.7350.0808
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2580.879
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.3450.562
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4040.38
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.6780.72
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.050.982
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3420.836
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5140.836
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2690.168
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ST6GAL1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolST6GAL1
NameST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Aliases ST6Gal I; SIAT1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase); ST6GalI; ST6N; B-cell an ......
Chromosomal Location3q27.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ST6GAL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolST6GAL1
NameST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Aliases ST6Gal I; SIAT1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase); ST6GalI; ST6N; B-cell an ......
Chromosomal Location3q27.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ST6GAL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ST6GAL1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolST6GAL1
NameST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Aliases ST6Gal I; SIAT1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase); ST6GalI; ST6N; B-cell an ......
Chromosomal Location3q27.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ST6GAL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolST6GAL1
NameST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Aliases ST6Gal I; SIAT1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase); ST6GalI; ST6N; B-cell an ......
Chromosomal Location3q27.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ST6GAL1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolST6GAL1
NameST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Aliases ST6Gal I; SIAT1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase); ST6GalI; ST6N; B-cell an ......
Chromosomal Location3q27.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ST6GAL1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolST6GAL1
NameST6 beta-galactosamide alpha-2,6-sialyltranferase 1
Aliases ST6Gal I; SIAT1; sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase); ST6GalI; ST6N; B-cell an ......
Chromosomal Location3q27.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ST6GAL1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.